Quick Answer
Traws Pharma, Inc. reported R&D Expense of $11.43 million for fiscal year 2023.
Traws Pharma, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2023 | $11.43M | +0.2% |
| 2022 | $11.41M | +56.3% |
| 2021 | $7.30M | -56.8% |
| 2020 | $16.90M | +8.8% |
| 2019 | $15.54M | -8.2% |
| 2018 | $16.92M | -11.5% |
| 2017 | $19.12M | -4.7% |
| 2016 | $20.07M | -22.5% |
| 2015 | $25.89M | -47.6% |
| 2014 | $49.42M | -1.5% |
| 2013 | $50.18M | -4.9% |
| 2012 | $52.76M | +133.2% |
| 2011 | $22.62M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| March 31, 2024 | $1.91M | -53.1% | -22.3% |
| September 30, 2023 | $2.46M | -31.5% | +0.2% |
| June 30, 2023 | $2.46M | +20.5% | -39.8% |
| March 31, 2023 | $4.08M | +103.8% | +13.6% |
| September 30, 2022 | $3.59M | +103.8% | +76.3% |
| June 30, 2022 | $2.04M | +10.0% | +1.8% |
| March 31, 2022 | $2.00M | +3.4% | +13.6% |
| September 30, 2021 | $1.76M | -58.0% | -4.8% |
- Traws Pharma, Inc. showed an increase of +0.2% in R&D Expense compared to the prior fiscal year.
- Over the 2011–2023 period, Traws Pharma, Inc.’s r&d expense has declined by 49.5% (from $22.62 million to $11.43 million).
- The most recent figure is from Traws Pharma, Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on April 1, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: